

COVID-19

Health Evidence Summary No.46

Kerry Millington & Samantha Reddin

Liverpool School of Tropical Medicine (LSTM) & Institute of Development Studies

26 May 2020

This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government departments to the latest relevant evidence and discourse on COVID-19 to inform and support their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make original documents easily accessible to decision makers which, if relevant to them, they should go to before making decisions.

Clinical characteristics and management

Publication date	Title/URL	Journal/Article type	Summary
25.05.20	Management of mild COVID-19: Policy implications of initial experience in India	medRxiv preprint (not peer reviewed)	<ul style="list-style-type: none"> • Study aimed at describing clinical characteristics and outcomes of admitted patients with mild COVID-19 illness in the initial phase of pandemic in India. • Conclusions - Patients with mild disease at presentation had a stable disease course and therefore such cases can be managed outside hospital setting.

Infection Prevention and Control

Publication date	Title/URL	Journal/Article type	Summary
25.05.20	Coronavirus (COVID-19) infection in children at a specialist centre:	medRxiv preprint (not peer reviewed)	<ul style="list-style-type: none"> • There is evolving evidence of significant differences in severity and outcomes of COVID-19 in children compared to adults. • In children presenting with pre-existing COVID-19 vulnerable medical conditions at a specialist centre, there does not

	outcome and implications of underlying high-risk comorbidities in a paediatric population		appear to be significantly increased risk of either contracting COVID-19 or severe complications, apart from those undergoing chemotherapy, who are over-represented.
--	---	--	---

Therapeutics

Publication date	Title/URL	Journal/Article type	Summary
22.05.20	Remdesivir for the Treatment of Covid-19 — Preliminary Report	New England Journal of Medicine Article	<ul style="list-style-type: none"> • A trial of the drug remdesivir showed that it shortens the recovery of people hospitalized for COVID-19. • John Beigel at the National Institutes of Allergy and Infectious Diseases in Rockville, Maryland, and his colleagues studied more than 1,000 people enrolled in a randomized, double-blind trial and found that those who took remdesivir had a median recovery time of 11 days, compared to 15 days for those who took a placebo.

Social Science

Publication date	Title/URL	Journal/Article type	Summary
21.05.20	Public knowledge, attitudes and practices towards COVID-19: A cross-sectional study in Malaysia	PLOS ONE Research article	<ul style="list-style-type: none"> • Cross-sectional online survey of 4,850 Malaysian residents was conducted between 27th March-3rd April 2020. • Respondents largely positive about way government was handling COVID-19. Most avoiding crowds and washing hands but fewer wearing masks. • The results highlight the importance of consistent messaging from health authorities and the government as well as the need for tailored health education programs to improve levels of knowledge, attitudes and practices.

Comments, Editorials, Opinions, Blogs, News

Publication date	Title/URL	Journal Article type	Author(s)
22.05.20	Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach	Lancet/ Correspondence	Praveen Tilangi, Devashish Desai, Adil Khan, Manish Soneja
21.05.20	Detection of SARS-CoV-2 in human breastmilk	Lancet/ Correspondence	Rüdiger Groß Carina Conzelmann et al.
1.06.20	Food insecurity will be the sting in the tail of COVID-19	Lancet Global Health/ Editorial	
26.05.20	Invest in planetary health to build resilience, urges global health community	UK Health Alliance on Climate Change'	
25.05.20	Trump's favoured drug shows no benefit — but another drug does	Nature / News	
22.05.20	Translating Science on COVID-19 to Improve Clinical Care and Support the Public Health Response	JAMA / Viewpoint	Carlos del Rio, Preeti Malani,
26.05.20	0.27% Rise in Infections Pushes Total of African COVID-19 Cases Over 115,000	All Africa / News	
26.05.20	Rwanda: COVID-19 - Researchers Discover New Method of Mass Testing	All Africa / News	

Guidelines, Statements & Tools

Publication Date	Title/URL	Source	Summary
22.05.2020	Framework for decision-making: implementation of mass vaccination campaigns in the context of COVID-19	WHO Interim Guidance	<ul style="list-style-type: none"> • Outlines a common framework for decision-making for the conduct of preventive and outbreak response campaigns • Considerations for implementing mass vaccination campaigns for prevention of increased risk of vaccine-preventable diseases (VPD)/high impact diseases (HID) among susceptible populations • Details the risks and benefits of conducting vaccination campaigns to respond to VPD/HID outbreaks

Dashboards & Trackers

Cases & deaths: Global	Cases & deaths: Regional	Cases & deaths: Country	Living evidence & policy maps	Current research including trials	Diagnostics	Treatments	Vaccines
WHO sitreps	WHO Africa	Ghana	COVID-NMA	WHO	FIND SARS-CoV-2 Test Tracker	Global COVID-19 Clinical Trial Tracker	CEPI
WHO dashboard	African Arguments	Indonesia	EPPI Centre	WHO International Clinical Trials Registry Platform (ICTRP)	FIND SARS-CoV-2 Diagnostic tests: performance data	US NIH registered clinical trials	Vaccine Centre LSHTM
Johns Hopkins University	European CDC	Nigeria CDC	Norwegian Institute of Public Health	Cytel	Serology-based tests for COVID-19	Solidarity trial	COVID-19 Oxford Vaccine Trial

WEF		Sierra Leone	Oxford C19 Government Response Tracker (OxCGRT)	US NIH	Our World in Data: C19 Testing	COVID-19 Therapeutics Accelerator	
Our World in Data		Singapore	Our World in Data: C19 Policy responses	COVID-evidence			
Global 5050		UK	IFPRI COVID-19 Policy Response Portal	Cochrane			
CEBM, University of Oxford		US		Clinicaltrials.gov			
Humanitarian Data Exchange				UKCDR			
Information is Beautiful							
LSHTM							
HealthMap (cases)							
The Commons Project							

C19 Resource Hubs

Global	Regional & Country	Academic journals & Publishers	Institutes/Centres/Funders/Others	Health Topics	Social Sciences
WHO COVID-19 pandemic	Africa CDC	Annals of Internal Medicine	LSTM	Stop TB Partnership	SSHAP
WHO risk communication	African Union	BMJ	LSHTM		IDA
WHO Q&A	Nigeria CDC	Bulletin of the WHO	ICL MRC Centre for Global Infectious Disease Analysis	Global Menstrual Collective	Disability and Inclusion
WHO Global research	GeoPoll : SSA	Cambridge University Press	ODI	SLH: Handwashing in low resource settings	Coregroup IDDC
COVID-19 Solidarity Response Fund	Global Health Network Africa	Cell Press	Johns Hopkins University	RBM Partnership	Ethics, health systems & COVID-19
UN	African Academy of Sciences	Cochrane	Center for Global Development		Social Development Direct C19 blog series
UN Women	Africa Evidence Network	Elsevier	CMMID Repository		

UNOCHA	OCHA Southern and Eastern Africa COVID-19 Digest	JAMA Network	Norwegian Institute of Public Health		
UNHCR		The Lancet	Oxford Centre for Evidence-based Medicine		
UNICEF		medRxiv and bioRxiv (Preprints)	HEART		
UNESCO		NEJM	UKRI		
UN WFP		Oxford University Press	Evidence Aid		
GOARN		PLoS	NIH		
EPI-WIN		SAGE journals	IFPRI Resources and Analyses of C19 Impact		
World Bank		Science	Prevent Epidemics		
Our World in Data		Springer Nature			
COVID-19 Narratives by David Nabarro		SSRN (Preprints)			
Reliefweb		Wiley			

Humanitarian OpenStreetMap Team					
Global Partnership for Sustainable Development Data					
WorldPop					
Flowminder					
COVID-END					
Premise COVID-19 Global Impact Study					

Online learning & events

Date	Title/URL	Online learning/event	Duration	Lead
04.06.2020 12pm ET	CGD Conversations on COVID-19 and Development: John Nkengasong	Event		CGD
Available now	WHO Academy and WHO Info mobile applications	Mobile app		WHO
Available now	COVID-19: Pandemics, Modelling and Policy	Online learning	2 weeks 2 hours weekly study	FutureLearn UNESCO UNITWIN Complex Systems Digital Campus/Open University

11.5.2020	COVID-19 Contact Tracing course	Online learning	5 hours	Johns Hopkins Bloomberg School of Health
7-28 May 2020	Virtual Evidence Weeks	5 sessions	1h 30	International Initiative for Impact Evaluation (3ie)
Tuesdays at 1700 CEST (Geneva time) & Thursdays 0830 CEST (Geneva time)	COVID-19 Open online brief with Dr David Nabarro	Event	1h	4SD
30.04.2020	Professor Chris Whitty's Gresham lecture on COVID-19	Event	1h 20	Gresham College
Available now	Emerging respiratory viruses, including COVID-19: methods for detection, prevention, response and control	Online learning	3 hours	WHO
Available now	Responding to COVID-19: Real-time training for the coronavirus disease outbreak	Online learning	Multiple self-paced course	WHO
25 May 2020	COVID-19: Tackling the Novel Coronavirus	Online learning	3 weeks 4 hours weekly study	FutureLearn LSHTM/UK PHRST
Available online now without mentors. Updated	COVID-19 Diagnostics and Testing	Online learning	3 weeks 3 hours weekly study	FutureLearn FIND/LSHTM/ASLM

version will commence early June 2020				
6 April 2020	COVID-19 Critical Care: Understanding and Application	Online learning	5 weeks 1 hour weekly study	FutureLearn University of Edinburgh & Royal College of Physicians of Edinburgh
Available now	COVID-19 supporting online courses	Online learning	Multiple self-paced course	BMJ Learning

Suggested citation

Millington, K.A. and Reddin, S. (2020). *COVID-19 Health Evidence Summary No.46*. K4D Evidence Summary. Brighton, UK: Institute of Development Studies.

Rapid review methodology

The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-2” OR “2019nCoV” OR “coronavirus”) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are included. Articles related to tackling the secondary impacts on other sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance.

The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter.

About this report

This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make original documents easily accessible to decision makers which, if relevant to them, they should go to before making decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. K4D services are provided by a consortium of leading organisations working in international development, led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and Conflict Response Institute (HCRI).

This evidence summary was prepared for the UK Government's Department for International Development (DFID) and its partners in support of pro-poor programmes. It is licensed for non-commercial purposes only. K4D cannot be held responsible for errors, omissions or any consequences arising from the use of information contained in this health evidence summary. Any views and opinions expressed do not necessarily reflect those of DFID, K4D or any other contributing organisation.



© DFID - Crown copyright 2020.